^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Mylotarg (gemtuzumab ozogamicin) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
AML:…Treatment induction…Option…Fludarabine 30 mg/m2 days 2-6, high-dose cytarabine (HiDAC) 2 g/m2 IV on days 4-6, and granulocyte colony-stimulating factir (G-CSF) subcutaneously (SC) daily days 1-7 plus a single dose of gemtuzumab ozogamicin 3 mg/m2 in first course
Secondary therapy:
cytarabine + fludarabine IV
